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Abstract
Fukuyama-type congenital muscular dystrophy (FCMD) is a severe form of muscular dystrophy accompanied by
abnormalities in the eye and brain. The incidence of FCMD is particularly high in the Japanese population.
Mutations in the fukutin gene have been identified in patients with FCMD. Fukutin is predicted to be a Golgi
apparatus resident protein and to be involved in the post-translational modification of cell-surface proteins.
Recently, progress has been made in our understanding of the molecular mechanisms by which the mutation
of fukutin leads to the phenotype of FCMD. Loss of function of fukutin results in defective glycosylation of
a-dystroglycan, a central component of the dystrophin-glycoprotein complex, leading to disruption of the linkage
between basal lamina and cytoskeleton. This disruption is implicated in the pathogenesis of both the MD and
brain anomalies in FCMD. Furthermore, genetic analyses have revealed that the spectrum of the FCMD phenotype
is much wider than originally thought. In this review, we summarize the diverging clinical phenotype of FCMD
and its molecular pathomechanisms.
Clinical features of FCMD and mutation of fukutin
Congenital muscular dystrophies (CMDs) are a group of
clinically and genetically heterogeneous muscular disor-
ders. Fukuyama-type congenital muscular dystrophy
(FCMD) is a unique disorder, which until recently had
been reported almost exclusively in the Japanese popula-
tion. FCMD is one of the most common autosomal
recessive disorders and is the second most common form
of muscular dystrophy in Japan after Duchenne MD. The
incidence of FCMD is particularly high in the Japanese
population (2.89 per 100,000 births) [1], and the carrier
rate in Japan is estimated to be one in 90. FCMD was
first described in 1960 by Fukuyama et al [2].
FCMD is characterized by severe MD accompanied by
brain malformation and ocular abnormalities. Patients
have generalized muscle weakness and hypotonia from
early infancy. Motor development is delayed, and the
maximum level of motor function, which is achieved
between 2 and 8 years of age, is unassisted sitting, slid-
ing on the buttocks, or sometimes standing with sup-
port. Thereafter, motor function declines severely
because of progressive muscle weakness and joint con-
tracture. Pseudohypertrophy of the calves and tongue
are often seen, as well as a dilated cardiomyopathy that
becomes symptomatic in the second decade of life [2].
Development of intellectual, cognitive and communi-
cative functions are also delayed. Most patients have
mental retardation, and about half of patients have epi-
lepsy [3]. The most common brain anomaly in FCMD is
cobblestone lissencephaly, which includes micropoly-
gyria, fibroglial proliferation of the leptomeninges, and
focal interhemispheric fusion. The neuronal lamination
of the normal six-layered cortex is lost. Hydrocephalus,
cerebellar cysts and hypoplasia of the corticospinal tract,
pons and cerebellar vermis are commonly present [2,4].
Ocular abnormalities such as retinal dysplasia, retinal
detachment, optic nerve atrophy, myopia and strabismus
are often seen on ophthalmological examination [5,6].
In 1993, Toda et al. initially mapped the FCMD locus
to chromosome 9q31-33 [7]. After localizing the gene to
a region of <100 kb containing the marker D9S2107,
they finally identified a mutation of the fukutin gene in
1998 [8]. A retrotransposal insertion of 3 kb of novel
tandemly repeated sequence into the 3’ untranslated
region of this gene constitutes the founder mutation. It
seems to derive from a single ancestor, and accounts for
>80% of the FCMD locus in the Japanese population.
This insertion causes a significant reduction in the level
of corresponding mRNA by rendering the mRNA* Correspondence: k-matsu@med.teikyo-u.ac.jp
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unstable, which causes the FCMD phenotype due to loss
of function [8]. In addition, several non-founder muta-
tions, including a nonsense or missense point mutation,
small deletion, small insertion and L1 insertion were
identified [9].
The fukutin gene spans >100 kb of genomic DNA,
and is composed of 10 exons. It encodes a protein of
461 amino acids with a predicted molecular weight of
53.7 kDa [8]. Native fukutin protein has not been detected
to date in skeletal muscle, probably because of its low
expression level; however, overexpressed fukutin localizes
to the Golgi apparatus in some cell lines [10]. Hydrophobi-
city plots and secondary structure analysis predict that
fukutin is an enzyme that modifies cell-surface glycopro-
teins or glycolipids, most probably through the attachment
of phosphoryl-sugar moieties [11]. However, the actual
enzymatic activity of fukutin has not yet been identified.
Instead, another possibility regarding its function has been
proposed. Fukutin colocalizes and forms a complex with
protein O-mannose b-1, 2-N-acetylglucosaminyltransfer-
ase (POMGnT1), a glycosyltransferase involved in the
synthesis of O-mannosyl glycan attached to a-dystrogly-
can (see below). In addition, POMGnT1 activity is
decreased in fukutin-deficient mouse tissues. Taken
together, these results indicate that fukutin may function
as a modulator of POMGnT1 [12].
Until the identification of the mutations in the fukutin
gene, it was hypothesized that FCMD might be a disorder
unique to the Japanese population. However, since 2003,
an increasing number of fukutin mutations have been
reported outside of Japan. Most cases are compound het-
erozygotes of point mutations, small deletions or duplica-
tions [13]. Recently, the founder mutation (the 3 kb
retrotransposal insertion) was also identified in the non-
Japanese East Asian population [14,15]. In addition, the
phenotype of the fukutin mutation has been found to
have a much broader spectrum than originally thought.
At one end, a condition that is more severe than typical
FCMD and resembles Walker-Warburg syndrome
(WWS) (see below), has also been found to be caused by
mutations of fukutin [16], whereas at the milder end,
there is a phenotype of limb-girdle MD that does not
involve brain anomaly or mental retardation [16]. Inter-
estingly, Murakami et al. reported patients with fukutin
mutations presenting with a dilated cardiomyopathy with
no or minimal MD nor mental retardation [17].
Structure and function of a-dystroglycan
The dystrophin-glycoprotein complex (DGC) is a multi-
meric protein complex located at the sarcolemma of mus-
cle fibers. The DGC consists of the dystroglycan complex,
sarcoglycan-sarcospan complex, syntrophin, neuronal
nitric oxide synthase, dystrobrevin and dystrophin. The
integrity of this complex is crucial for the normal function
and viability of muscle cells. Dystroglycan is encoded by a
single gene, Dag1, located on human chromosome 3p21
and cleaved into two proteins, a- and b-dystroglycan, by
post-translational processing [18]. a-dystroglycan is a
highly glycosylated, extracellular peripheral-membrane
protein with a molecular weight of 156 kDa in skeletal
muscle, and binds to several proteins of the extracellular
matrix (ECM) including laminin, agrin and perlecan, and
synaptic proteins such as neurexin and pikachurin [18,19].
The transmembrane protein b-dystroglycan, with a mole-
cular weight of 43 kDa, anchors a-dystroglycan to the
extracellular surface of the plasma membrane. The cyto-
plasmic domain of b-dystroglycan interacts with dystro-
phin, a large cytoplasmic protein that binds to F-actin.
Thus, dystroglycan plays a central role in the DGC to sta-
bilize the plasma membrane by acting as an axis that links
the ECM to the cytoskeleton.
a-dystroglycan is composed of distinct three domains:
the N-terminal, mucin-like and C-terminal domains.
The N-terminal domain is cleaved by the proprotein
convertase, furin, and secreted outside cells [20,21]. The
mucin-like domain is highly glycosylated by O-linked
oligosaccharides, and the sugar-chain moiety constitutes
up to two-thirds of the molecule. Chiba et al. reported
that O-mannosyl glycan (Siaa2-3Galb1-4GlcNAcb1-
2Man), is attached to the serine or threonine residues
on a-dystroglycan as a major sialylated O-linked oligo-
saccharide structure. This unique glycan is necessary for
the binding with its ligands (a-dystroglycan) [22].
Recently, it was found that the mannose residue of the
O-mannosyl glycan is modified by an ancient type of
phosphoryl glycan, and that this modification is also
necessary for binding to laminin [23].
Dystroglycan not only mechanically stabilizes the sar-
colemma against contraction-stretch stress, but also
plays a role in signal transduction. The b-dystroglycan
cytoplasmic domain binds to growth factor receptor-
bound protein 2 (Grb2), an adaptor protein involved in
signal transduction and cytoskeletal organization [24].
Furthermore, in vitro experiments have shown that a
tyrosine residue in the PPXY motif of the C terminus
of b-dystroglycan is phosphorylated in an adhesion-
dependent manner, and that this tyrosine phosphoryla-
tion abolishes the binding of dystrophin and its homo-
log, utrophin, to the PPXY motif [25]. This tyrosine
phosphorylation of b-dystroglycan in turn recruits the
SH2 domain-containing signaling proteins such as the
c-Src, Fyn, c-Src tyrosine kinase (Csk), non-catalytic
region of tyrosine kinase adaptor protein (NCK) and
Src homology 2 domain-containing (SHC) proteins
[26]. Recently, it was reported that the binding of lami-
nin to a-dystroglycan causes signaling through the
dystroglycan-syntrophin-Grb2-SOS1-Rac1-PAK1-JNK
cascade which is initiated by Src family kinases, and
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also causes syntrophin tyrosine phosphorylation to
begin signaling [27].
Dysfunction of a-dystroglycan in FCMD and
related disorders
In 2001, Hayashi et al. reported that the immunoreactiv-
ity of the antibody against the sugar-chain moiety of a-
dystroglycan is severely reduced in the skeletal muscle
of patients with FCMD, suggesting defective glycosyla-
tion of a-dystroglycan [28]. Subsequently, Michele et al.
showed, using an antibody against the core protein of
a-dystroglycan, that in the skeletal muscle of patients
with FCMD, a-dystroglycan is hypoglycosylated as a
result of mutations in fukutin. Intriguingly, these
authors also showed that the binding activity of a-dys-
troglycan for the ligands such as laminin, agrin or neur-
exin is severely reduced [29]. Furthermore, Yoshida-
Moriguchi et al. recently reported that the postpho-
sphoryl modification of the phosphorylated O-mannose
is defective in the skeletal muscle of patients with
FCMD [23]. These findings are consistent with previous
studies reporting that the sugar-chain moiety of a-dys-
troglycan (O-mannosyl glycan in particular) is crucial
for the interaction between a-dystroglycan and laminin
interaction. Disruption of the linkage between a-dystro-
glycan and laminin is predicted to have profound effects
on muscle-cell viability, because it causes destabilization
of the sarcolemma against contraction-stretch stress,
hampers signal transduction, and inhibits the assembly
of ECM proteins (Figure 1).
The same pathomechanisms underlie several types
of MD other than FCMD. A homolog of fukutin,
fukutin-related protein (FKRP), was cloned, and point
mutations in the FKRP gene were identified in
patients with congenital muscular dystrophy 1C
(MDC1C) [30]. MDC1C, prevalent in white popula-
tions, is a severe form of CMD, occasionally associated
with brain or ocular anomalies. A milder form of
limb-girdle muscular dystrophy (LGMD) 2I is an alle-
lic disorder to MDC1C. The enzymatic activity of
FKRP has not yet been identified. Muscle-eye-brain
(MEB) disease, found mainly in Finland, is typically
characterized by severe brain and ocular abnormalities
and CMD. Mutations of the POMGnT1 gene have
been found in patients with MEB [31]. POMGnT1 cat-
alyzes the GlcNAcb1-2Man linkage in the O-mannosyl
glycan of a-dystroglycan.
WWS is one of the most severe types of CMD, and
is accompanied by marked brain malformation and
structural eye abnormalities. Typically, the brain of
patients with WWS is more severely affected than the
brain of patients with FCMD or MEB. Mutations in
protein O-mannosyltransferase (POMT)1 and POMT2
are present in patients with WWS. POMT1 and
POMT2 form a complex, and are involved in the first
step of O-mannosyl glycosylation in which mannose is
attached to the serine or threonine residues of a-dys-
troglycan [32,33]. MDC1D, another form of CMD, is a
rare disorder characterized by severe MD accompanied
by brain malformation. Mutations of the LARGE (like-
glycosyltransferase) gene have been identified in
patients with MDC1D. Interestingly, a recent paper
reported that LARGE is involved in the phosphoryl glyco-
sylation of O-mannnosyl glycan attached to a-dystrogly-
can [23]. In all the MDs described above, biochemical data
have confirmed that dysfunction of a-dystroglycan under-
lies the pathogenesis, and therefore they are collectively
called the a-dystroglycanopathies.
Figure 1 The dysfunction of a-dystroglycan in Fukuyama-type
congenital MD (FCMD). (A) The normal dystrophin-glycoprotein
complex (DGC) in skeletal muscle. a-dystroglycan binds to laminin
via the O-linked glycan chain moiety, including Siaa2-3Galb1-
4GlcNAcb1-2Man and a phosphoryl glycan attached to the
mannose. Details of the postphosphoryl glycan modification are still
unknown. The N-terminal domain of a-dystroglycan is cleaved by
furin and secreted. (B) The DGC in FCMD. The mutation in fukutin
causes defects in postphosphoryl modification of the O-linked
glycan, resulting in disruption of the linkage between a-
dystroglycan and laminin, and leading to destabilization of the
sarcolemma. The modification of O-linked mannose by Siaa2-
3Galb1-4GlcNAcb remains to be elucidated in FCMD.
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One of the prominent hallmarks of FCMD is the pre-
sence of brain anomalies, that is, of cobblestone lissence-
phaly [2,4]. It is of particular importance to note that the
glia limitans-basal lamina complex is frequently disrupted,
and neuroglial tissues protrude through the cleft into the
subarachnoid space in the brain of patients with FCMD
[34]. This disruption of the glia limitans-basal lamina com-
plex causes migration defects of neurons, and eventually
results in further anomalies such as the disarray of cere-
bral cortical layering or the formation of the unique
appearance of the micropolygyria. In the brain, fukutin is
expressed by neurons and glial cells, and colocalizes with
a-dystroglycan [35,36]. The fukutin-deficient chimeric
mouse, a model of FCMD, exhibits essentially the
same brain anomalies as seen in patients with FCMD,
with defective glycosylation of a-dystroglycan also pre-
sent in the mouse brain [37]. Interestingly, the specific
disruption of dystroglycan in mouse astrocyte or epi-
blast results in very similar neuropathological findings
to those of FCMD [38-40]. In these mice, the laminin-
binding activity of a-dystroglycan is severely reduced
in the brain. Taken together, these observations
strongly support the idea that the functional defect in
a-dystroglycan is central to the pathogenesis of brain
malformation in FCMD (Figure 2).
Conclusion
A broad spectrum of clinical presentations is now attrib-
uted to mutations in the fukutin gene. Recent progress in
molecular genetics and biochemistry in this area has con-
firmed that defective post-translational modification of
a-dystroglycan caused by the fukutin mutation underlies
the pathogenesis of MD. The defective glycosylation
results both in degeneration of the skeletal muscle and in
migration defects of neurons in the brain through disrup-
tion of the a-dystroglycan-laminin linkage. Consequently,
amelioration or upregulation of the dystroglycan function
may be the most suitable molecular target for therapies
for FCMD. The putative glycosyltransferase LARGE is
now known to restore the defective dystroglycan function
[41,42], thus, it may be of benefit in the treatment of
FCMD. Further experiments are necessary to shed
further light on the pathomechanism of FCMD and to
facilitate the development of a therapeutic strategy.
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